Zolmitriptan NDC 71626-101

NDC codes

FDA NDC Directory

Product NDC (as listed)71626-101Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71626-0101Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
71626-101-06	71626010106	6 BLISTER PACK in 1 CARTON (71626-101-06) / 1 TABLET, FILM COATED in 1 BLISTER PACKMarketed from May 30, 2018

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Zolmitriptan
Generic name (nonproprietary): zolmitriptan
Active ingredients: Zolmitriptan — 2.5 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Medstone Pharma LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 207867
Marketing start: May 30, 2018
Listing expires: Dec 31, 2026
Other FDA classes: Serotonin 1b Receptor Agonists (Mechanism)Serotonin 1d Receptor Agonists (Mechanism)
Identifiers: Product ID 71626-101_f538eaaa-1f19-4f02-b744-4749e899b54dSPL ID f538eaaa-1f19-4f02-b744-4749e899b54dSPL set ID c970dd17-abdb-4fac-8de8-984e388b498cRxCUI 200193, 200194UNII 2FS66TH3YWUPC 0371626102035
Pharmacologic class: Serotonin-1b and Serotonin-1d Receptor Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N471626010106 followed by a unit qualifier and the quantity

Package 71626-0101-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 25, 2023.

Indications (excerpt from the label)

Zolmitriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use Only use zolmitriptan tablets if a clear diagnosis of migraine has been established. If a patient has no response to zolmitriptan tablets treatment for the first migraine attack, reconsider the diagnosis of migraine before zolmitriptan tablets are administered to treat any subsequent attacks. Zolmitriptan tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of zolmitriptan tablets have not been established for cluster headache. Zolmitriptan is a serotonin (5-HT) 1B/1D receptor agonist (triptan) indicated for the acute treatment of mig…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 207867

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 207867
Product	Strength	Form · route	Labeler	Product NDC
Zolmitriptan	Zolmitriptan 5 mg/1	Tablet, Film coatedOral	Medstone Pharma LLC	71626-102
Zomigzolmitriptan	Zolmitriptan 2.5 mg/1	Tablet, Film coatedOral	Amneal Pharmaceuticals LLC	60846-130
Zomigzolmitriptan	Zolmitriptan 5 mg/1	Tablet, Film coatedOral	Amneal Pharmaceuticals LLC	60846-133
Zolmitriptan	Zolmitriptan 2.5 mg/1	Tablet, Film coatedOral	PLD Acquisitions LLC DBA Avma Pharma Solutions	63548-0101
Zolmitriptan	Zolmitriptan 5 mg/1	Tablet, Film coatedOral	PLD Acquisitions LLC DBA Avma Pharma Solutions	63548-0102